Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

麗珠醫藥集團股份有限公司
LIVZON PHARMACEUTICAL GROUP INC.*
(a joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 1513)

VOLUNTARY ANNOUNCEMENT
OBTAINMENT OF THE DRUG REGISTRATION CERTIFICATE FOR WANDAI TANG GRANULES

Recently, Sichuan Guangda Pharmaceutical Manufacturing Co., Ltd. (四川光大製藥有限公司) (**"Sichuan Guangda"**), a subsidiary of Livzon Pharmaceutical Group Inc.* (麗珠醫藥集團股份有限公司) (the **"Company"**), received the Drug Registration Certificate (Certificate No.: 2026S03950) issued by the National Medical Products Administration of the People's Republic of China* (國家藥品監督管理局) (**"NMPA"**) in respect of the drug registration application for Wandai Tang Granules (the **"Product"**). The relevant particulars are announced as follows:

KEY PARTICULARS OF THE DRUG REGISTRATION CERTIFICATE

Generic Name: Wandai Tang Granules

Main ingredients: Atractylodes macrocephala rhizome stir-fried with earth (土炒白朮), dry-fried Chinese yam (清炒山藥), ginseng (人參), bran-fried Atractylodes rhizome (麩炒蒼朮), etc.

Dosage form: Granules

Specification: Each sachet is equivalent to 22.13 g of prepared Chinese medicinal herbs

Registration Classification: Class 3.1 traditional Chinese medicine

Marketing Authorization Holder: Sichuan Guangda Pharmaceutical Manufacturing Co., Ltd.

Manufacturer: Sichuan Guangda Pharmaceutical Manufacturing Co., Ltd.

Drug Registration Standard No.: YBZ00762026

National Drug Approval Number: 國藥准字 C20260024

Validity Period of Approval Number: Until 25 October 2031

Approval conclusion: Upon examination in accordance with the Drug Administration Law of the People's Republic of China and relevant provisions, the Product complies with the relevant requirements for drug registration. The Product is approved for marketing and a Drug Registration Certificate is issued. The quality standards, package insert, labelling and manufacturing process shall comply with the attachments. After the Product is marketed, the following work shall continue to be completed: the marketing authorization holder shall fulfil its primary responsibilities, implement relevant risk prevention and control measures, strengthen post-marketing studies on efficacy and safety, and conduct additional relevant non-clinical studies where necessary. The safety-related sections of the package insert shall be revised and improved in a timely manner based on the clinical and non-clinical safety data collected. After the Product is marketed, the following work shall continue to be completed: (1) the marketing authorization holder shall fulfil its primary responsibilities and continue stability studies in accordance with the submitted stability study protocol to ensure consistent drug quality; and (2) it is recommended that further studies be conducted on the quality control methods for dry-fried Chinese yam (清炒山藥), Bupleurum root (柴胡) and carbonized Schizonepeta spikes (荊芥穗炭), that the chromatographic conditions for the characteristic chromatogram continue to be optimized, that quality control parameters and testing methods be consolidated and optimized, and that the quality standards for the formulation be further studied and improved.

DRUG DEVELOPMENT AND RELATED CONDITIONS

The formulation of the Product originates from Fu Qing Zhu's Gynecology (《傅青主女科》), authored by Fu Shan during the Qing dynasty, and has been included in the Catalogue of Ancient Classical Prescriptions (First Batch) (《古代經典名方目錄（第一批）》) issued by the National Administration of Traditional Chinese Medicine. According to the original text, it is a classical prescription for the treatment of leukorrhea, with the following therapeutic functions and indications: "To tonify the spleen, soothe the liver, resolve dampness and alleviate leukorrhea. It is indicated for leukorrhea associated with liver qi stagnation, spleen deficiency and downward flow of dampness-turbidity. Symptoms include white or pale-yellow vaginal discharge that is thin and odourless, a pale complexion, fatigue, loose stools, a pale tongue with a white coating, and a moderate or soft and

weak pulse." The core therapeutic approach of the formulation is to tonify the spleen, soothe the liver, resolve dampness and alleviate leukorrhea.

The formulation has been documented in numerous historical gynecological case records. In modern times, it has also been the subject of various clinical and experimental studies and has been included in the standard textbook Formulas of Traditional Chinese Medicine (《方劑學》). As a commonly used gynecological prescription, it is widely used for profuse, thin vaginal discharge and conditions such as chronic pelvic inflammatory disease, vaginitis and cervicitis in patients presenting with the traditional Chinese medicine syndrome of spleen deficiency with excessive dampness.

As at the date of this announcement, the cumulative direct investment expenses in research and development for Wandai Tang Granules amount to approximately RMB4.4746 million.

IMPACT ON THE COMPANY AND RISK WARNING

The Product is the first of its kind to be approved for marketing in China and is also the Company's second Class 3.1 new drug to receive approval. It further enriches the Company's product pipeline and will help enhance the market competitiveness of the Company's products. Following its launch, the Product can facilitate the wider clinical application of this classical prescription, help improve the provision of clinical diagnosis and treatment services in traditional Chinese medicine, and make medication more convenient for patients.

As the Product has only recently obtained drug registration approval, it will not have a material impact on the Company's operating results in the near term.

The production and sales of drugs are affected by factors such as national policies and the market environment and are subject to uncertainties. Investors are advised to exercise caution when making investment decisions and to pay attention to investment risks.

By order of the Board
Livzon Pharmaceutical Group Inc.*
麗珠醫藥集團股份有限公司
Liu Ning
Company Secretary

Zhuhai, China
27 October 2026

As at the date of this announcement, the executive directors of the Company are Mr. Liu Daping (Chairman and President) and Mr. Tang Yanggang (Vice Chairman); the non-executive directors of the Company are Mr. Lin Nanqi and Mr. Qiu Qingfeng; the employee representative director of the Company is Ms. Ran Yongmei; and the independent non-executive directors of the Company are Mr. Luo Huiyuan, Ms. Cui Lijie, Ms. Wang Zhiyao and Ms. Kang Li.

** For identification purpose only*